
Inmode Ltd (INMD) Stock Forecast & Price Target
Inmode Ltd (INMD) Analyst Ratings
Bulls say
InMode Ltd demonstrated robust sales activity with the sale of 971 systems in the second quarter of 2025, contributing to a global installed base of approximately 28,855 units, marking a 3.4% increase from the previous quarter. The company's operating margin improved to 27.5%, surpassing estimated expectations and reflecting a year-over-year increase of 40 basis points. Additionally, the domestic sales growth of 9% in the second quarter, an improvement from a 7% decline in the first quarter, underscores the rising consumer and physician interest in the expanding aesthetics market.
Bears say
InMode Ltd is facing a challenging financial outlook as its gross margins are expected to contract, despite currently remaining among the highest in the med tech sector. The company's projected revenue growth is anticipated to slow, with a compound annual growth rate (CAGR) of less than 5% due to underwhelming performance from existing products and sluggish adoption of new ones. Additionally, while there has been an improvement in operating margins, the overall trend indicates that earnings per share (EPS) growth may lag behind revenue growth, signaling potential profitability concerns.
This aggregate rating is based on analysts' research of Inmode Ltd and is not a guaranteed prediction by Public.com or investment advice.
Inmode Ltd (INMD) Analyst Forecast & Price Prediction
Start investing in Inmode Ltd (INMD)
Order type
Buy in
Order amount
Est. shares
0 shares